Methylprednisolone sodium phosphate | 5015-36-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Methylprednisolone sodium phosphate
• 英文别名: disodium;[2-[(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-6,10,13-trimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] phosphate
• CAS: 5015-36-1
• 化学式: C22H29Na2O8P
• 分子量: 498.4
• InChiKey: FVKLXKOXTMCACB-VJWYNRERSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -5.34
• 重原子数：
  33
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  147
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Linkage of agents using microparticles
  申请人：Green Howard

  公开号：US20060110379A1

  公开（公告）日：2006-05-25

  Methods, products and kits are provided for attaching agents to a skin surface via microparticles using endogenous or exogenous transglutaminase.

  提供了一种方法、产品和套件，可通过内源或外源性谷氨酰胺转移酶使用微粒子将药剂附着到皮肤表面。
• Drug Delivery System, its Preparation Process and Use
  申请人：Deng Yihui

  公开号：US20110064794A1

  公开（公告）日：2011-03-17

  A protein-phospholipid dispersion preparation in a drug delivery system is provided, in which the weight ratio of protein to phospholipid is 1:300-300:1 and the particle size is between 5 nm and 1000 nm. The preparation process of the said preparation contains the mixture of protein phase and phospholipid phase and the homogenization process. The said drug delivery system can be used in many different pharmaceutical agents.

  提供了一种蛋白磷脂分散制剂的药物递送系统，其中蛋白质与磷脂的重量比为1:300-300:1，粒径在5纳米至1000纳米之间。所述制剂的制备过程包括蛋白质相和磷脂相的混合和均质化过程。该药物递送系统可用于许多不同的药物制剂。
• DHA-pharmaceutical agent conjugates
  申请人：Luitpold Pharmaceuticals, Inc.

  公开号：EP1466628A1

  公开（公告）日：2004-10-13

  The invention provides conjugates of cis-docosahexaenoic acid and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

  本发明提供了顺式-二十二碳六烯酸的共轭物和用于治疗非中枢神经系统疾病的药剂。本发明还提供了将药剂选择性靶向所需组织的方法。
• A DRUG DELIVERY SYSTEM, ITS PREPARATION PROCESS AND USE
  申请人：Shenyang Pharmaceutical University

  公开号：EP2243495A1

  公开（公告）日：2010-10-27

  A protein-phospholipid dispersion preparation in a drug delivery system is provided, in which the weight ratio of protein to phospholipid is 1:300-300:1 and the particle size is between 5 nm and 1000 nm. The preparation process of the said preparation contains the mixture of protein phase and phospholipid phase and the homogenization process. The said drug delivery system can be used in many different pharmaceutical agents.

  本发明提供了一种药物输送系统中的蛋白质-磷脂分散制剂，其中蛋白质与磷脂的重量比为 1:300-300:1，粒径在 5 纳米至 1000 纳米之间。所述制剂的制备过程包括蛋白质相和磷脂相的混合和均质过程。上述给药系统可用于多种不同的药物制剂。
• Engineered receptor/ligand system for delivery of therapeutic agents
  申请人：University of Florida Research Foundation, Incorporated

  公开号：US11000597B2

  公开（公告）日：2021-05-11

  Provided herein are compositions and methods related to targeted delivery of a therapeutic or diagnostic agent to a subject utilizing an engineered receptor-ligand system, such as an engineered dockerin-cohesin system. As described herein, previously-developed targeted delivery systems for delivering therapeutic and diagnostic agents to a tissue of interest have drawbacks that have not been addressed to date. For example, with respect to the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB), both of which hamper delivery of agents to the brain, others have relied on the use of endogenously expressed receptors, like the transferrin receptor, to assist the agent across the barriers.

  本文提供了与利用工程受体-配体系统（如工程 dockerin-cohesin系统）向受试者靶向递送治疗剂或诊断剂有关的组合物和方法。如本文所述，以前开发的将治疗剂和诊断剂靶向输送到相关组织的靶向输送系统存在迄今尚未解决的缺点。例如，血脑屏障（BBB）和血-脑脊液屏障（BCSFB）都会阻碍将药剂输送到大脑，因此其他药物依赖于使用内源性表达的受体（如转铁蛋白受体）来帮助药剂穿过屏障。